Refractory Cancer Clinical Trial
Official title:
An Exploratory Single-center, Open-label , Clinical Study of Apatinib in Patients With Local Progressive/Metastatic Refractory Thyroid Cancer
This is a single-center, open-label, single arm，exploratory clinical trial evaluating the efficacy and safety of Apatinib in patients with local progressive/metastatic refractory thyroid cancer.
This is a single-center, open-label, single arm，exploratory clinical trial evaluating the
efficacy and safety of Apatinib in patients with local progressive/metastatic refractory
thyroid cancer.
The primary endpoint is objective response rate(ORR),the secondary endpoints include
progression-free-survival(PFS)；disease control rate(DCR);serum Tg、TgAb、calcitonin；safety.
If any case happens as following,including withdrawing informed consent form(ICF)、unbearable
toxicity or adverse reactions、other conditions which investigators think the patients are
unsuitable to go on trail,the patient will not go on trial any longer,or every subject will
obtain study treatment until tumor progress with CT/MRI proof.The indicators of efficacy and
safety will be always observed during the trail process.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03336931 -
PRecISion Medicine for Children With Cancer
|
||
| Completed |
NCT00530192 -
Molecular Profiling Protocol (SCRI-CA-001)
|
Phase 0 | |
| Recruiting |
NCT05852717 -
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT06229340 -
Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations
|
Phase 2 | |
| Completed |
NCT00551850 -
A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients
|
Phase 1 | |
| Recruiting |
NCT06104488 -
A Study of Avutometinib for People With Solid Tumor Cancers
|
Phase 1 | |
| Terminated |
NCT04092179 -
Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06184035 -
A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06024603 -
Individualized Treatments in Adults With Relapsed/Refractory Cancers
|
N/A | |
| Recruiting |
NCT05859074 -
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
|
Phase 1 | |
| Recruiting |
NCT05864144 -
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03187288 -
Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS
|
Phase 1 | |
| Terminated |
NCT01320280 -
BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer
|
Phase 2 | |
| Completed |
NCT03441100 -
TCR-engineered T Cells in Solid Tumors: IMA202-101
|
Phase 1 | |
| Recruiting |
NCT05359445 -
IMA401 TCER® in Recurrent and/or Refractory Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT03686124 -
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04337580 -
Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04310345 -
Impact of Human-Animal Interactions on Children With Life-Threatening Conditions and Their Parents
|
N/A | |
| Recruiting |
NCT05669430 -
A Study of GV20-0251 in Patients With Solid Tumor Malignancies
|
Phase 1 | |
| Not yet recruiting |
NCT06208657 -
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
|
Phase 1/Phase 2 |